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EDITORIAL REVIEW
Growth hormone, insulin-like growth factor and the kidney
Structure and biochemistry
Human growth hormone is a protein encoded by a gene cluster
composed of five loci found in a 50 kb portion of chromosome 17
[1]. One locus encodes the two main circulating variants of human
growth hormone protein, the most abundant form of human
growth hormone being a single polypeptide of 191 amino acids
with two disulfide bridges and molecular weight of 22,000 daltons
or 22 kD. Alternative mRNA splicing gives rise to a 176 amino
acid peptide, the 20 kD human growth hormone variant, which
accounts for 5 to 10% of total pituitary growth hormone [2].
Another locus of the growth hormone gene cluster encodes an
additional growth hormone variant, different by 13 amino acids
from the main 22 kD growth hormone peptide. This growth
hormone peptide is produced by the placenta and represents the
predominant circulating form of growth hormone in late preg-
nancy [31. The other three loci correspond to chorionic somato-
mammotropin genes.
Up to 50% of circulating serum growth hormone is bound to
proteins [4, 5]. The 22 kD growth hormone peptide is vehiculated
by a high-affinity binding protein which is a single chain glyco-
protein whose structure corresponds to the extracellular domain
of the growth hormone receptor [6]. This growth hormone binding
protein may be originated from proteolytic cleavage of the
membrane growth hormone receptor and/or be directly synthe-
sized from an alternatively spliced messenger RNA (mRNA)
produced from the same gene as the receptor [7, 8]. Truncated
forms of growth hormone receptor mRNA have been identified in
animal species having analogous high affinity growth hormone
binding protein such as rat [91, mouse [10, 11], and rabbit [12].
The great majority of circulating 20 kD variant of growth hor-
mone is vehiculated by a low-affinity growth hormone binding
protein which is not related to the growth hormone receptor [13,
14].
The mature human growth hormone receptor consists of 620
amino acids with an extracellular domain of 246 amino acids and
the transmembrane and intracellular domains containing 24 and
350 amino acids, respectively [15]. It has been found widely
distributed in a variety of tissues from different species of animals,
the liver being the tissue containing the highest growth hormone
receptor concentrations [16, 17]. There seems to be only one
growth hormone receptor gene [18—20] and it has been cloned
from hepatic tissue.
Previously known as somatomedin C, insulin-like growth factor
I (IGF-I) is a single chain peptide of 70 amino acids and molecular
weight of 7.5 kD [21, 22]. Its structure is almost identical in
different mammalian species and is closely related to that of
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insulin and insulin-like growth factor II (IGF-II) [23]. IGF-I is
encoded from one single gene located on chromosome 12 [24, 25].
Human and rat IGF-I genes contain at least five exons, separated
by four introns ranging in size from 1.9 to 50 kb [26]. Several
different IGF-I mRNAs result from alternative processing of the
primary gene transcript [27]. In rat liver, at least 12 different IGF-I
mRNAs have been identified [28]. In humans, the IGF-I gene is
transcribed and processed into two types of mRNA, which are
translated in two different IGF-I precursor peptides of 153 and
195 amino acids [21]. Little is known on the synthesis of the IGF-I
peptide from these precursors.
Circulating IGF-I is vehiculated by carriers called binding
proteins (IGFBP) in such a way that virtually no free IGF-I is
measurable in serum and less than 1% of IGF-I activity in serum
is unbound [20, 29]. Six classes of IGFBP have been identified in
humans [30—32]. IGFBP-3 was first isolated from human serum
and comprises two glycosylated binding proteins migrating at 41.5
and 38.5 kD and, in association with IGF-I or IGF-II and an
acid-labile non-IGF binding subunit of approximately 85 kD, form
a high molecular weight ternary complex of 150 kD. The other
three types of IGFBP, IGFBP-1, -2 and -4, are proteins with a
molecular weight of approximately 30 kD, 34 kD, and 24 kD,
respectively, that associate with IGFs to form binary complexes of
about 40 kD.
The IGF-I receptor is a tetrameric glycoprotein, structurally
similar to the insulin receptor, located on the plasma membranes
of target cells. It is composed of two alpha-subunits containing the
binding domain and two beta-subunits containing tyrosine kinase
domains. Phosphorylation of the beta-subunit, which occurs as a
result of coupling of IGF-I to the alpha-subunit, is likely related to
the transmission of the IGF-I signal across the plasma membrane,
although the intracellular signaling mechanisms are not clearly
determined [33, 34].
Neuroendocrine control of growth hormone secretion
The pulsatile nature of growth hormone secretion is one of the
most notable and important characteristics of growth hormone
physiology. A typical pattern of growth hormone concentrations
in the blood is one of conspicuous pulses superimposed upon a
background of relatively low tonic secretory concentrations. In
laboratory animals, there is a clear sexual dimorphism of growth
hormone secretion [351. Male animals show extremely low back-
ground concentrations with high amplitude pulses occurring at
regular intervals of approximately three hours. Female animals
show a significantly higher background concentration with mod-
erate-sized pulses occurring at random intervals. The mechanisms
which translate these differences in pulsatile growth hormone
secretion to sexual differences in body growth remain to be
determined.
The ultimate source of control of the pulsatile growth hormone
rhythm is the brain, by means of neurohormones. The final
common pathway of neuronal connections is located in the
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hypothalamus. Specific regulatory nuclei include the ventromedial
and arcuate nuclei for growth hormone releasing hormone, and
the periventricular nucleus for the inhibitory neurohormone,
somatostatin [36, 37]. Axons of the neurosecretory neurons
converge on the median eminence. The neurohormones are
secreted into perivascular spaces around the primary capillary
plexus of the hypophyseal portal system. Blood borne neurohor-
mones are carried by the portal veins to the secondary capillary
plexus in the anterior pituitary gland where they cause the
synthesis and release of growth hormone, or the inhibition of its
secretion (Fig. 1).
Growth hormone releasing hormone (GHRH) is a peptide
presenting in both 40 and 44 amino acid forms. The initial
purifications were from ectopic GHRH produced by tumors of the
pancreas [38, 39]. These forms were later found to be nearly
identical to human hypothalamic GHRH [40]. Rat hypothalamic
GHRH shows 67% homology with the 44 amino acid human
GHRH [41]. The peptides act via receptors on the membranes of
the growth hormone-producing cells. These "somatotropes" make
up slightly more than 35% of the total number of anterior
pituitary cells [42]. Cyclic AMP is thought to be the primary
second messenger for the stimulation of growth hormone release,
although calcium-dependent mechanisms are also known to be
involved [43]. Besides release of growth hormone, GHRH also
stimulates growth hormone synthesis by means of increased gene
transcription [44].
The low concentrations of growth hormone between pulses is
most likely the result of tonic somatostatin output from the
hypothalamus. This neurohormone was initially purified as a
tetradecapeptide [45], but may be more active as a 28 amino acid
form [46]. The mechanism of action is thought to be by means of
inhibition of the cAMP system, but might also involve a decrease
in membrane permeability to calcium [47].
Once secreted by the pituitary gland, growth hormone (Fig. 1)
causes its growth promoting effects indirectly by the production of
Fig. 1. Growth hormone (GH) is secreted from
the anterior lobe of the pituitaFy gland and acts at
its target sites via insulin-like growth factor-I
(IGF-I). Liver is a major organ for the
production of IGF-I. Unlike most peptide
hormones, IGF-I is not stored in granules, but
is released as it is synthesized. Circulating IGF-I
exerts little influence on its hepatic production
because normal liver is devoid of IGF-I
receptors. OH acts directly and/or in
conjunction with IGF-I at the chondrocytes of
the growth plate of the long-bone to promote
linear growth. GH induces local production of
IGF-I at target sites such as the chondrocytes of
the growth plate of long bones to act as a
paracrine/autocrine factor. Synergistic action of
both GH and IGF-I at the growth plate
stimulates linear growth. GH and IGF-I act as
negative feedback (interrupted line) to the
hypothalamus, inhibiting further secretion of
GH. The central nervous system control GH
secretion by growth hormone releasing hormone
(GHRH) and growth hormone inhibiting
hormone (GHIH), also known as somatostatin.
insulin-like growth factor-I (IGF-I). Although IGF-I is produced
in large quantities by the liver in response to growth hormone,
there is a strong probability that growth hormone effects are
mediated by the local production of IGF-I at the target tissues
[48]. IGF-I would then act by a local paracrine or autocrine effect
on the tissues themselves. IGF-I is also known to have a potent
negative feedback effect on growth hormone secretion both by an
action on the hypothalamic control mechanisms and a direct
negative effect on pituitary gland secretion of growth hormone
[49].
Recent studies have shown that infusion of heterologous
growth hormone causes a synchronization of endogenous growth
hormone pulsatile release [50]. The negative feedback of growth
hormone on its own secretion is thought to occur via its influence
on the output of GHRH and somatostatin from the hypothalamus
[51, 52]. From these studies, and others, it can be hypothesized
that the rhythm of growth hormone secretion involves a tonic
secretion of somatostatin to produce the low background concen-
tration of growth hormone, with occasional bursts of GHRH
secretion producing the growth hormone pulses. The GHRH
bursts may or may not be accompanied by a coordinated decrease
in the output of somatostatin. The potential for the neural
integration of these signals by means of interactions of blood-
borne growth hormone and IGF-I, as well as the neurohormones
themselves by means of synaptic contacts certainly exists, but
remains to be clearly defined.
Adrenergic mechanisms within the hypothalamus are known to
modulate growth hormone secretion. Alpha-2 receptors are
thought to be involved in the stimulation of growth hormone
secretion by either the stimulation of GHRH output [53] or
inhibition of somatostatin release [54]. Beta-adrenergic systems
are involved with growth hormone control both within the hypo-
thalamus and directly at the level of the pituitary gland. By means
of cyclic AMP (cAMP) production, stimulation of the beta-
adrenergic system, like that of GHRH itself, results in growth
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hormone release. This effect is relatively small, however, in
comparison to beta-adrenergic inhibition of growth hormone
release [55]. This latter effect is probably the result of somatosta-
tin secretion from the hypothalamus [56]. The inhibition of growth
hormone release by the beta-adrenergic system is the basis for the
augmentation of growth hormone release by beta-blockers, such
as propranolol and atenolol [57].
Steroid hormones are also known to be important modulators
of growth and growth hormone secretion. With respect to sex
steroids, it is commonly accepted that gonadectomy of the male
leads to decreased growth, while gonadectomy of the female is
likely to facilitate growth [35]. The mechanisms underlying these
effects, however, are anything but clear. Concerning growth
hormone secretion, removal of the testes decreases GHRH
responsiveness of dispersed pituitary cells in vitro [58]. This can be
at least partially reversed by treatment with testosterone. Estro-
gen treatment of gonadectomized males leads to a decreased
GHRH responsiveness of the pituitary cells in vitro. On the other
hand, low dose estrogen administration has the capability to
increase the growth hormone response to pharmacological stimuli
in humans [59]. This effect might be related to previous findings of
increased numbers of somatotropes in pituitary glands of estro-
gen-treated animals [60], as well as to increased growth hormone
mRNA expression [61] and growth hormone synthesis [62].
Androgens, on the other hand, might augment growth hormone
secretion by increasing mRNA for GHRH in the hypothalamus
[63]. The growth hormone content of pituitary glands from male
animals is also known to be significantly larger than that of
females. In general, it might be concluded that the effects of male
sex steroids are facilitatory to growth hormone secretion and
growth, secondary to the hypothalamic secretion of GHRH as
well as by augmention of growth hormone content of the pituitary
gland. Estrogenic effects are less straightforward. Whereas ovari-
ectomy leads to the potential for increased growth, and estrogen
treatment can decrease GHRH responsiveness of pituitary cells in
vitro, estrogen in low doses augments the growth hormone re-
sponse to pharmacological stimuli.
Adrenal steroids also have significant effects on growth and
growth hormone secretion. Chronic glucocorticoid treatment is
desirable for its immunosuppressive effects, but is also well known
to significantly retard body growth [64]. A concensus is now being
reached that growth hormone responsiveness to releasing stimuli
is most commonly inhibited in vivo [65]. This is probably due to
glucocorticoid stimulation of somatostatin secretion from the
hypothalamus. An interesting paradox is that pituitary cells from
glucocorticoid-treated animals are clearly facilitated in their re-
sponse to GHRH [66, 67]. Another interesting phenomenon is
that acute treatment with glucocorticoids leads to a spontaneous
release of growth hormone within a fairly brief period of time [68].
The long-term effect, however, remains one of inhibition. In this
respect, glucocorticoids probably inhibit growth by a long-term
inhibition of growth hormone secretion by means of increased
somatostatin secretion from the hypothalamus. But acute stimu-
lation of growth hormone release and facilitation of pituitary
gland growth hormone secretory mechanisms is also an expected
paradoxical effect of these steroids. The possibility that glucocor-
ticoids might influence GH target tissue by changing levels of GH
receptors or its mRNA [69] and/or by changing IGF-I production
should not be overlooked.
The relationship of growth hormone secretion to nutrition is
also an important aspect of the neuroendocrine control of this
hormone. Because the anorexia of uremia gives rise to malnutri-
tion, the effects of nutrition on growth hormone secretion de-
serves consideration here. Fasting in humans is well known to
result in increased growth hormone secretion [70]. This fasting-
induced increase also occurs in rabbits [71], pigs [72], gonadecto-
mized sheep [73], and steers [74]. The increased growth hormone
output is most likely to be due to a decrease in somatostatin
secretion by the hypothalamus [73].
Complete clarification of the mechanisms underlying the rela-
tionship of nutrition to growth hormone secretion, however, has
not yet been achieved. This is particularly true with respect to
understanding the actual growth retardation resulting from fast-
ing and undernutrition. The rat, the model in which many of the
relevant studies have been performed, shows a unique response to
fasting, that is, a decrease in growth hormone secretion. This
condition may actually be highly pertinent to the overall growth
retarding effects of undernutrition. Hypothetically, this decrease
in growth hormone secretion may be due either to an increase in
somatostatin or a decrease in GHRH. Previous studies have
shown that neither the content of somatostatin itself [75] nor its
mRNA [76] in the hypothalamus is increased by fasting in the rat.
Concentrations of somatostatin in the peripheral circulation are
known to be increased during fasting, however, and may be due to
an increase in gastrointestinal and pancreatic production of the
hormone itself [75] as well as its mRNA [77]. Besides these
changes in somatostatin in the peripheral circulation, hypotha-
lamic concentrations of GHRH mRNA have been found to be
profoundly decreased after fasting [76]. The content of GHRH
itself, however, was found to be unchanged. These data indicate
that the decrease in growth hormone observed in the rat after
fasting might be due to an increase in somatostatin in the
peripheral circulation related to changes in the gastrointestinal
system, and potentially to alterations in hypothalamic GHRH
mRNA.
Other factors might also be involved in growth hormone
secretion during fasting. Thyroid hormone is known to be impor-
tant to the production of growth hormone by pituitary cells [78],
and a decrease in triiodothyronine during fasting might be related
to the decrease in growth hormone mRNA in the pituitary gland
under these conditions [79]. Retinoic acid is also known to act
with thyroid hormone to facilitate growth hormone production in
pituitary cells [801, and, in this respect, the growth impairment
associated with vitamin A deficiency might be related to a
decrease in growth hormone production. Disruption of growth
hormone secretion may also be related to the growth impairment
and decreased IGF-I concentrations observed in deficiencies of
lysine [81], potassium [82], and zinc [83], as well as in an excess of
selenium [84].
In summary, the pulsatile nature of growth hormone secretion
is important to its physiological effects. The brain, more specifi-
cally the hypothalamus, controls growth hormone release by a
pattern of neurosecretion of GHRH and somatostatin. These
hypothalamic mechanisms are profoundly influenced by a number
of factors, some of which include growth hormone itself, IGF-I,
adrenergic mechanisms, sex and adrenal steroids, and food intake.
Along with direct effects of these and other substances on the
pituitary gland, the end result is a growth hormone secretory
pattern which is significantly related to the course of normal body
growth and metabolism.
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Table 1. Actions of growth hormone on carbohydrate and lipid
metabolism
I. Insulin-like actions (mostly rapid)
A. In vitro effects
1. Increased glucose uptake, glucose oxidation, and glucose
conversion to fatty acids in adipose tissue, adipocytes and
muscle.
2. Inhibition of adrenaline-stimulated lipolysis in adipose tissue.
B. In vivo effects
1. Transient hypoglycemia in hypophysectomized dog and rat
and growth hormone-deficient children.
2. Transient fall in free fatty acids.
II. Anti-insulin-like actions (mostly slow)
A. In vitro effects
1. Decreased glucose oxidation and conversion to fatty acids in
adipose tissue from dwarf mice (after 4 hr) and in 3T3
adipocytes (after 24—48 hr).
2. Refractoriness to the insulin-like actions of growth hormone.
3. Increased lipolysis in adipose tissue (after 1 hr).
B. In vivo effects
1. Hyperglycemia, especially in dogs.
2. Impaired glucose tolerance.
3. Lipolysis.
4. Resistance to the actions of insulin.
In many cases, growth hormone shows directly opposite actions, usually
insulin-like in the short-term and anti-insulin-like in the long-term. Many
actions are primarily marked in growth hormone-deficient animals or
humans. From: WArns M: Mechanism of action of growth hormone, in
Hormones and TheirActions, Part II, edited by Coonl BA, KING RJB, VAN
OCR MOLEN HI, Amsterdam, Elsevier Science Publishers, 1988, pp
265—294, used with permission.
Physiology of growth hormone
Growth hormone is the main regulatory hormone of body's
growth and it is also involved in carbohydrate, lipid, and protein
metabolism. It is generally accepted that its longitudinal growth
stimulating effect is mostly mediated by IGF-I whereas its actions
on carbohydrate and fat utilization result from a direct hormonal
effect (Table 1) [851.
In vitro studies have shown a different ability of tissues to
metabolize free growth hormone. Thus, at neutral pH, human
growth hormone is proteolytically degraded by rat skeletal muscle
and thyroid gland preparations whereas it is stable in liver and
kidney homogenates [86]. In vivo, renal catabolism accounts for
about 70% of the plasma turnover of growth hormone in rats [87].
Growth hormone is extensively filtered by the glomeruli but only
a minimum amount is eliminated in urine because most of filtered
growth hormone is reabsorbed and catabolized by the tubular
epithelium cells. Twenty-four-hour urinary growth hormone elim-
ination has been shown to correlate well with serum growth
hormone profiles in normal prepubertal children but not in those
in mid to late puberty [88].
The physiologic role of growth hormone binding proteins
(GHBP) is uncertain. The majority of studies have focused on the
high affinity growth hormone binding protein because it vehicu-
lates the major form of circulating growth hormone, the 22 kD
peptide. Serum concentrations of GHBP are growth hormone
dependent in such a way that they show a pulsatile pattern which
parallels that of endogenous serum growth hormone, the great
majority of growth hormone pulses being followed by GHBP
pulses within 30 minutes in normally growing children [89]. On the
other hand, prolonged administration of exogenous growth hor-
mone to growth hormone-deficient children has been shown to
induce a sustained elevation of serum growth hormone binding
protein concentrations [90]. Mean values of serum growth hor-
mone binding protein are also influenced by an individual's age,
the serum concentrations increasing progressively in childhood
and reaching adult values after 20 years of age [17]. During
puberty, no modification or slight decline of growth hormone
binding protein concentrations is observed, probably as a result of
the negative effect of sex steroids such as testosterone and
estrogens [91, 92]. The function of growth hormone binding
protein is likely related to its ability to diminish the amount of free
circulating growth hormone and, accordingly, prolong the hor-
mone half-life. Studies in rats [93, 94] have demonstrated that
exogenous growth hormone binding protein decreases the degra-
dation rate and extravascular availability of growth hormone. In
vitro experiments [4, 95, 961 have also shown that growth hormone
binding protein competes with the growth hormone for the
occupancy of growth hormone receptor, and the presence of
increasing serum concentration of growth hormone binding pro-
tein is associated with a decreased ability of growth hormone to
bind to growth hormone receptors. In addition, GHBP has also
been found in the cytosol and nucleus [97, 98], suggesting a
potential modulating effect of the carrier protein on the growth
hormone action at the target tissue. It has also been suggested that
circulating values of growth hormone binding protein could reflect
the status of tissue growth hormone receptor. This might be true
for liver but not for other peripheral tissues whose contribution to
the total serum concentration of growth hormone binding protein
is minimal, if any [6].
Growth hormone receptor is present in most rat tissues, a close
correlation having been found between growth hormone binding
and the concentrations of growth hormone receptor mRNA [16,
99]. Control of growth hormone receptor gene expression is
complex and dependent on tissue-specific, developmental, hor-
monal, and nutritional factors [15}. Binding of growth hormone
induces phosphorylation of the receptor [100, 101]. The further
changes occurring in the cell at the molecular level are mostly
unknown. It is known that following binding to its receptor,
growth hormone is internalized in the intracellular compartment.
It was previously thought that intracellular growth hormone was
directed toward lysosomal degradation. Recent investigations
detecting growth hormone binding protein in the nucleus [981
suggest that nuclear growth hormone receptors may mediate the
transcriptional effects of growth hormone, while the membrane
growth hormone receptors are responsible for the short-term
metabolic actions [102].
Physiology of growth hormone administration
Growth hormone administration transiently increases glucose
oxidation by adipocytes [3]. Because this short-term insulin-like
effect is physiologically unimportant [103], growth hormone has
traditionally been considered as a "diabetogenic" hormone be-
cause, in contrast to IGF-I [104, 105], prolonged administration of
growth hormone causes hyperglycemia and lipolysis in the pres-
ence of elevated insulin concentrations [1021. In addition, growth
hormone-deficient children characteristically tend to be mildly
obese and their adipocytes, although reduced in number, contain
a higher than normal amount of fat. These anomalies are reversed
with growth hormone supplementation. As shown by Salomon et
al [106] in adults with growth hormone deficiency and by Rudman
et al [107] in men over 60 years old, treatment with human growth
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hormone induces changes in body composition such as increased
lean body mass and decreased fat mass. Hypercholesterolemia is
not an usually observed complication in humans treated with
growth hormone [106, 107]. However, elevated serum cholesterol
concentrations have been shown in rats having very high growth
hormone circulating concentrations as a result of tumor-secreted
growth hormone [108]. On the other hand, recent investigations
have demonstrated that growth hormone stimulates hepatic syn-
thesis of apolipoprotein-B mRNA, the essential apolipoprotein of
chylomicrons, intermediate-, low-, and very low-density lipopro-
teins, suggesting a role of growth hormone in the regulation of
lipid and lipoprotein metabolism.
Growth hormone administration has been shown to stimulate
synthesis of IGF-I mRNA in most rodent tissues [21, 109]. Peak
concentrations of IGF-I mRNA are achieved three to nine hours
after a single growth hormone injection, although the degree of
stimulation depends on the tissue and the subclass of mRNA.
Nutrition and hormonal factors also influence IGF-I production.
In rats, fasting gives rise to reduced number of hepatic growth
hormone receptors, and decreased concentrations of both growth
hormone receptor mRNA and IGF-I mRNA [110]. The effect of
fasting on IGF-I mRNA, IGF-I receptor mRNA, and IGF-I
receptor binding is not uniform, differing in kidney, muscle,
gastrointestinal tract, testis, and brain [111]. Protein malnutrition
reduces hepatic IGF-I mRNA, but by a different mechanism
because growth hormone binding to liver is not depressed,
suggesting that protein restriction may induce a postreceptor
resistance to the growth hormone action [112]. Whatever the
underlying mechanism, fasting and malnutrition result in low
serum concentrations of IGF-I and a subnormal increment of
serum IGF-I concentrations in response to growth hormone
administration [112, 113].
Physiology of insulin-like growth factor-i
IGF-I exerts its action at the cellular level by binding to its
receptor which undergoes a conformational change that results in
activation of tyrosine kinase activity and phosphorylation of
specific proteins [33]. IGF-I, IGF-II, and insulin overlap in their
receptor specificity. Insulin can bind IGF receptors with approx-
imately 1% the affinity of IGF-I and, in turn, IGF-I and IGF-II
can cross react with insulin receptor by approximately 2%. Affinity
of IGF-II for the IGF-I receptor is about one third that of IGF-I
[23]. In vitro the three peptides stimulate glucose and amino acid
uptake, protein synthesis, thymidine incorporation into DNA, and
cell proliferation [29]. In vivo, the biological potency of IGFs and
insulin differs depending on the type of receptor present on the
cell surface. For instance, IGF-I is not a potent stimulator of
lipogenesis because adipocytes do not contain IGF-I receptors
[23]. Likewise, circulating IGF-I exerts no influence on its hepatic
production because normal liver is devoid of IGF-I receptors. On
the contrary, hepatic IGF-I receptors have been found in fetus
and liver in a state of regeneration, suggesting that, in these
conditions, liver growth is influenced by IGF-I action [114, 115].
On the other hand, the stage of development markedly influences
the expression of the IGF-I receptor gene because a dramatic
decrease of IGF-I receptor mRNA concentrations has been found
in rat tissues during postnatal life [116].
The effects of IGF-I on target tissues can be carried out by
circulating IGF-I, functioning as an endocrine factor, and by
locally produced IGF-I, acting as an autocrine/paracrine factor.
Table 2. Potential functions of insulin-like growth factor-I binding
proteins (IGFBP)
1. Reservoir of active hormone
2. Maintenance of a constant concentration of hormone
3. Targeting to specific tissues
4. Modulation of biological action
a) Inhibition
b) Potentiation
5. Metabolism of the hormone
a) Protection from degradation
b) Removal of hormone from tissues
From: HINTZ RL: Role of growth hormone and insulin-like growth
factor-binding proteins. Horm Res 33:105—110, 1990 (used with permis-
sion).
The relative importance of both forms of action varies from tissue
to tissue and with the stage of development. Autocrine and
paracrine actions are probably more important in tissues with
IGF-I receptors and high IGF-I concentrations such as lung,
kidney, and ovarian granulosa cells, and where anatomical barri-
ers limit entry of IGF-I from the circulation as in testis and the
central nervous system. In these organs, local production of IGF-I
appears to be mainly related to processes of tissue hypertrophy
and repair [21].
The function of the IGFBP in the metabolism of IGF-I is not
well understood (Table 2) [117]. Most of serum IGF-I forms part
of the 150 kD complex, whereas a minor fraction is vehiculated
into the 40 kD complex, and almost undetectable amounts
circulate as free IGF-I. The half-life in serum of these three
fractions of IGF-I is different: 12 to 15 hours for the 150 kD
material, 20 to 30 minutes for the 40 kD complex, and 10 to 12
minutes for the free IGF-I [31]. These differences suggest varying
bioavailability of IGF-I for the different serum fractions. Likewise,
only free IGF-I and the 40 kD IGF-I complex enter glomerular
ultrafiltrate and are catabolized in the proximal tubule cells [118].
Only 30% of urinary IGF-I is found in the free form [21]. The 150
kD IGFBP and total IGF-I are parallel throughout life with low
concentrations of both at birth, rising during childhood and
puberty, and declining as age increases [119]. This pattern is the
inverse to that found for the 40 kD IGFBP complex which has
high concentration early in life, with a decline during childhood,
lowest value during puberty and a slight elevation with increasing
postpubertal age [120, 121]. Whereas 150 kD IGFBP concentra-
tions are growth hormone dependent, there is an inverse relation
between growth hormone production and serum concentrations
of the 40 kD complex [122]. Recent reports [105, 123] have shown
elevation of serum IGFBP-1 concentrations following recombi-
nant human IGF-I administration in healthy humans, suggesting
that this effect is likely mediated by IGF-I induced suppression of
insulin concentrations. Insulin may also play a still undetermined
role in the regulation of IGFBP-2 [123].
IGF-I bound to IGFBP-3 in the 150 kD material cannot cross
the capillary barrier [31]. Therefore, the 150 kD complex likely
serves as a circulating reservoir of IGF-I and controls its bioavail-
ability [32] in such a way that it compensates for the fact that,
unlike most peptide hormones, IGF-I is not stored in secretory
granules for secretion by exocytosis but is released as it is
synthesized. Binding of IGF-I to IGFBP-3 depends on a serum
protease whose activity varies acutely in different conditions [120].
The physiological role of the 40 kD IGFBP complex is not clear.
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a,b
Pair-fed-2
Fig. 2. Data from deconvolution analysis of pulsatile growth hormone(growth hormone) secretion in the control (N = 9), acidotic (N = 9),
pair-fed-i, given food in the morning (N = 8), and pair-fed-2, given food in
the evening (N = 6) groups. Values for mean growth hormone secretory
pulse amplitude (height), pulse area (mass), pulse number, and total
growth hormone secreted as pulses (total growth hormone secretion) are
shown. Data are expressed as means SEM. In each panel, values without
common letters ("a", "b", or "c") are significantly different (P = 0.05 or
lower). (From Challa A, Krieg RJ Jr, Thabet MA, Veldhuis JD, Chan
JCM: Metabolic acidosis inhibits growth hormone secretion in the rat.
Mechanisms of growth retardation. Am J Physiol 265:E547—E553, 1993;
used with permission of the American Society of Physiology).
It likely functions as a transport protein which shuttles IGF-I from
the circulation to the target cells facilitating the action of IGF-I at
the tissue level [29]. This would explain why the amount of 40 kD
complex is relatively greater in the fetus and infants, periods of
life in which growth rate is maximum [31]. In addition, it has been
suggested that the small IGFBP complex might direct the IGF-I to
appropriate sites of action or clearance and modulate the IGF-I
activity in a tissue-specific manner [32, 124, 125]. The hypothesis
that IGF-I is guided to the cells by the 40 kD IGFBP complex is
supported by the similar immunoreactive distribution of IGF-I
and IGFBP-1 in fetal tissues [120].
Growth hormone secretion and IGF-I expression in acidosis
Using multiple parameter deconvolution analysis, growth hor-
mone secretion was found to be inhibited in rats during metabolic
acidosis (Fig. 2). This inhibition of growth hormone secretion may
be a proximal cause of the growth failure with renal tubular
acidosis. The growth hormone secretory pulse areas for both
acidotic and pair-fed animals are reduced [126].
Another recent study [127] demonstrated that the marked
Variables
Control
(N = 5)
Pair-fed
(N = 5)
Acidotic
(N = 5)
Serum IGF-I ng/ml
Serum IGF-II nglml
818.0 130.9a
18.8 18a,b
233.6 45.6"
10.4 l.4c
411.8 57•3d
11.8 15d
IGFBP-3 ng/ml
Hepatic IGF-1
11.5 9.0
1.4 O.3'
10.1 2..6
0.6 0.2c
11.9 6.2
0.9 0.3c
mRNA (ADU)
Hepatic growth hormone 2.9 1.6a 1.7 0.4 1.4 0.9"
receptor mRNA (ADU)
ADU is arbitrary densitometric units. Values are presented in mean
SD. (Reprinted by permission, Cu&u A, Ci-iA W, KRIEG RJ JR, THABET
MA, Liu F, Hirz RL, Cit".i JCM: Effect of metabolic acidosis on the
expression of insulin-like growth factor and growth hormone receptor.
Kidney mt 44:1224—1227, 1993.)
In each row values with the same superscript are not significantly
different. Different superscripts indicate different concentrations of statis-
tical significance: a vs. b, P < 0.005; b vs. c, P < 0.01; a vs. d, P < 0.025;
bvs. d,P <0.05.
impairment in weight gain in Sprague-Dawley rats made acidotic
with ammonium chloride ingestion is correlated with inhibition of
hepatic IGF-1 expression. The data in the pair-fed animals
support the possibility that protein/calorie malnutrition may play
an important role in this inhibition in pituitary growth hormone
secretion and reduced IGF-1 expression. However, acidosis inhib-
its growth hormone in a specific fashion because acidosis does not
affect the half-life or the number of pulses of growth hormone
[126]. In addition, despite the suppression of hepatic IGF-I
mRNA in both acidotic and pair-fed animals (Table 3), the
hepatic growth hormone receptor mRNA is depressed only in the
acidotic rats [127].
Growth hormone/IGF-I axis and the kidney
The major site of renal synthesis of IGF-I is located at the
collecting duct [128—130] where growth hormone enhances IGF-I
gene expression [131]. Collecting ducts do not have receptors for
IGF-I [131]. Therefore, IGF-I action must be exerted at other
sites where IGF-I receptors are present, such as mesangial cells
[132—134], and proximal tubular cells [135, 136]. Receptors for
growth hormone have also been found in the basolateral mem-
brane of proximal tubule cells [137], suggesting a direct action of
circulating growth hormone at this kidney location.
The current availability of biosynthetic human growth hormone
has raised enormous interest on the therapeutic benefits of
promoting catch-up growth in uremic children, but the potential
of growth hormone-induced deterioration of renal function is a
concern. This apprehension on the renal effects of growth hor-
mone is in part supported by the fact that growth hormone
transgenic mice have a shortened life expectancy, renal failure
being the primary cause of death [138, 1391. In growth hormone
transgenic mice [140—142], renal lesions characterized by large
kidneys with tubular atrophy, enlarged glomeruli and glomerulo-
sclerosis are found. These lesions are absent, or they are much
milder, in IGF-I transgenic mice [140, 141, 143]. Increased kidney
size and glomerulosclerosis have also been demonstrated in rats
with pituitary tumor transplants [103] and humans with acromeg-
aly [144], and in both situations the circulating concentrations of
growth hormone are markedly elevated. In aging rats, the severity
a,b
b,cI i 1•r/
a
T
Table 3. Effects of metabolic acidosis on insulin-like growth factors
(IGFs), IGF-binding protein-3 (IGFBP), mRNA of IGF-I and growth
hormone (growth hormone) receptor
b
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of nephrosclerosis was correlated with the plasma concentrations
of growth hormone [145]. In the renal ablation uremia model,
proteinuria, hypertension and severe renal scarring were observed
120 days after subtotal nephrectomy. In contrast, growth hor-
mone-deficient rats appear to be partly protected against glomer-
ular sclerosis and tubulointerstitial scarring found in control rats
120 days after subtotal nephrectomy [146]. Transgenic mice
carrying different portions of bovine growth hormone demon-
strated different body growth and glomerulosclerosis [147].
In addition, a considerable body of evidence points to a
significant role of locally produced IGF-I in the regeneration of
the proximal tubule following ischemic injury in the rat [148] as
well as in the compensatory growth of remaining renal tissue after
unilateral nephrectomy [149]. Increased rat kidney IGF-I content
have been found, three to five days following partial nephrectomy
[146, 149, 1501. Conversely, data on IGF-I mRNA in the remain-
ing kidney tissue are not uniform, high [149] and unchanged [151]
concentrations having been reported. From a different point of
view, IGF-I acting through an autocrine mechanism might be an
important pathogenic factor in certain proliferative glomerulone-
phritis [1341. Growth hormone-independent synthesis and release
of IGF-I has been demonstrated in cultures of mesangial cells
[134, 152] with an increased amount of mesangial cell mitosis
occurring in response to the locally produced IGF-I.
It has been well established in animals [153] and humans [154,
155] that growth hormone increases glomerular filtration rate and
renal plasma flow in a parallel manner. This effect is mediated by
IGF-I [156—158] which likely enhances renal plasma flow resulting
from reduced vascular resistance of afferent and efferent glomer-
ular arterioles [159]. The hemodynamic action of IGF-I on renal
vascular resistance is not dependent on intrarenal angiotensin
because it is not blocked by angiotensin-converting enzyme inhib-
itors [160]. By contrast, it is blocked by indomethacin administra-
tion, which suggests a mediator role of vasodilatory eicosanoids
[161]. Hirschberg et al [162] investigated the effects of recombi-
nant human IGF-I administration on renal hemodynamics in rats,
showing that the increased glomerular filtration rate was due not
only to increased single nephron plasma flow rate, but also to a
marked increment in the glomerular ultrafiltration coefficient to
twice the control values. More recently, Hirschberg et a! [163]
demonstrated that in human subjects, recombinant human IGF-I
administration stimulated renal plasma flow and the glomerular
filtration rate, increased microproteinuria and tubular phosphate
reabsorption, but caused no change in calcium reabsorption.
Both growth hormone and IGF-I stimulate proximal tubular
gluconeogenesis [20]. Sodium and water retention has long been
shown to occur in humans receiving growth hormone [164]. This
effect persists in the absence of adrenal glands [165]. It is
completely suppressed by prior administration of actinomycin D
[166], and may be, at least in part, due to direct stimulation of
tubular Na-K-ATPase activity [167]. IGF-I has been shown to
enhance sodium transport in the toad bladder [168].
Growth hormone secretion and expression in chronic
renal insufficiency
Studies on growth hormone secretion in chronic renal insuffi-
ciency have been inconclusive and have often led to contradictory
results [169, 170], possibly due to the pulsatile nature of growth
hormone secretion, increased retention and catabolism in uremia,
variable activities of the binding proteins and the effects of stress,
undernutrition and other influences not being carefully examined
or controlled. Single sample techniques, or even short term
samplings, may be inappropriate to characterize the state of the
growth hormone secretory system in uremia. Comparison of
uremics to controls of equivalent nutritional status (pair-fed) is
necessary for accurate assessment, because underfeeding pro-
foundly affects growth hormone secretion [171, 172].
Using highly specific assays, Haffner et a! [173] demonstrated
an inverse hyperbolic correlation between plasma growth hor-
mone concentrations and the metabolic clearance rate. Recent
data by Santos et al [174] indicated that pituitary cells of uremic
rats responded normally to growth hormone releasing hormone.
Krieg et al [175] also showed that the half-life of growth hormone
in the circulation of uremic rats was significantly greater than
either untreated controls or pair-fed controls using deconvolution
analysis of pulsatile growth hormone secretion in stable uremic
rats. There was no apparent difference between uremic and
control animals in the intervals between growth hormone secre-
tory pulses, but the mass of growth hormone secretion by pair-fed
animals was significantly less than that of the untreated controls
[175]. In uremic animals, the growth hormone mass was not
different from that of pair-fed controls. These new data suggest
that growth hormone secretory episodes might be significantly
different in uremia compared to pair-fed controls with respect to
half-life and the numbers of pulses.
Preliminary data have also shown that pituitary growth hor-
mone mRNA expression is reduced in the uremic animals and
that pituitary IGF-1 receptor mRNA expression is enhanced
[176]. These studies utilized pituitary tissues collected and homog-
enized in guanidine isothionate in the uremic rat model. Further-
more, reductions in pituitary growth hormone receptor and IGF-1
receptor gene expression [177] have been demonstrated at a food
restriction to 60% of control intakes, which is a comparable food
intake as in uremic animals [178] and humans [174].
Growth hormone resistance in chronic renal insufficiency
Growth hormone resistance is presumed to be present in
uremia. No study has found subnormal serum growth hormone
concentrations in uremic animals [179] or humans [180]. In
addition, insulin-like growth factors have also been shown to be
normal in uremic children [181]. However, the uncertain reduc-
tions in renal excretion associated with varying degrees of chronic
renal insufficiency and the variable rates of catabolism render the
interpretation of serum growth hormone and IGF-I concentra-
tions less reliable in the uremic condition. A significant reduction
in liver IGF-I mRNA was recently demonstrated in uremic
animals compared to pair-fed and control animals [182]. After
growth hormone administration, the expected increase in liver
IGF mRNA in both controls and pair-fed animals did not
materialize in the uremic animals. This first direct evidence of
tissue resistance to growth hormone in uremia by Chan, Valerie
and Chan [182], and later confirmed by others [183], provided a
powerful rationale for the use of recombinant human growth
hormone in uremic children.
It is possible that in uremia, the growth promoting effect of
exogenously administered recombinant human growth hormone
results from changes of IGF-I mRNA and/or IGF-I in tissues
other than liver, such as kidney, bone and muscle, where the
paracrine/autocrine action of IGF-I is of critical importance in
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growth promotion [184]. In addition, the growth hormone recep-
tor was markedly reduced in livers of uremic animals but not in
control or pair-fed animals [182, 183]. This relationship persisted
after growth hormone administration. It is also possible that the
effect of exogenous recombinant human growth hormone is
exerted on the IGF-I binding proteins [185, 186], which was likely
to exert profound effects on the availability and function of IGF-I.
Recent findings [187, 188] suggest that, in the serum of patients
with chronic renal failure, there is a disequilibrium between the
concentrations of IGF-1 binding protein-3 (IGFBP-3) and IGF-I,
in such a way that there is an excess of unsaturated low-molecular
weight forms (19 and 14 kD) of IGFBP-3 not seen in normal
serum. Accordingly, there is less circulating bioactive IGF-I. It has
also been proposed [181, 189] that accumulation of IGFBPs in
chronic renal failure impedes normal longtudinal growth either by
inhibiting IGF-I actions by a paracrine mechanism or in other yet
unidentified IGF inhibitors.
Reduced growth hormone binding in uremic rats demonstrated
by Finidori, Postel-Vinay and Kleinknecht [190] and in uremic
children demonstrated by Postel-Vinay et al [191], together with
the documentation of tissue resistance to growth hormone dem-
onstrated by Chan et al [182] and Tonshoff et al [183] led to the
suggestion that in uremia, the defect in growth hormone receptor
binding is extended to the transcriptional level. Liver growth
hormone receptor mRNA was unaffected in hypophysectomized
rats, even in the face of 50% reduction in growth hormone binding
compared to intact animals [192]. Such data suggested that in
hypophysectomized rats, the growth hormone receptor function
was controlled by its translation rather than by its transcription
[193].
Fasting or the lack of insulin caused a reduction in the
abundance of liver growth hormone receptor for mRNA, unaf-
fected by low protein intake [194]. Because defective growth
hormone receptor can lead to growth hormone insensitivity as
manifested in Laron syndrome [195], it has been suggested that
decreased growth hormone receptor function may contribute to
the growth hormone resistance in uremia.
Growth hormonellGF-I, vitamin D and bone interactions
Growth hormone and IGF-I synergistically act at the growth
plate of long bones to stimulate longitudinal growth in humans
and animals. Direct action of growth hormone on cartilage is
suggested by the presence of growth hormone receptors in growth
plate chondrocytes [1961 and expression of growth hormone
receptor mRNA in response to growth hormone in monolayer
cultures of epiphyseal chondrocytes [1971. Growth hormone in-
duces local production of IGF-I as demonstrated by increased
concentrations of IGF-I [198] and IGF-I mRNA [199, 200] in the
rat's growth plate in response to growth hormone administration,
chondrocyte IGF-I mRNA being more effectively stimulated by
pulsatile than constant growth hormone concentrations [2011. In
addition, the growth stimulating effect of growth hormone on rat
bones has been shown to occur after a time lag longer than two
days and be abolished by administration of a monoclonal antibody
to IGF-I [202]. Circulating IGF-I also appears to play a major role
as stimulus of longitudinal growth because the increase in tibial
bone growth and cartilage plate width obtained by local adminis-
tration of growth hormone is significantly less than that observed
in response to systemic growth hormone [21]. According to the
hypothesis proposed by Green, Morikawa and Nixon [203] and
supported by other investigators [204—2061, growth hormone and
IGF-I act on different cells in the growth plate. It is postulated
that growth hormone induces differentiation of precursor cells
toward chondrocytes enabling the expression of IGF-I mRNA,
locally produced IGF-I acts through autocrine and paracrine
mechanisms to stimulate clonal proliferation of adjacent differen-
tiated chondrocytes. This "dual effector" hypothesis has been
challenged by Hunziker, Wagner and Zapf [207], who have
recently presented evidence that IGF-I is also capable of stimu-
lating stem cells of growth plate cartilage in hypophysectomized
rats, although IGF-I is not as effective as growth hormone.
The action of growth hormone and IGF-I on bone is not
exclusively restricted to cartilage cells. IGF-I receptors have been
found in osteoblast-enriched cultures from fetal rat parietal bone
[208] and in vitro studies have shown stimulation of bone, collagen
and non-collagen protein synthesis in response to IGF-I [209]. In
addition, growth hormone has been found to increase IGFBP-2
and IGFBP-4 concentrations in rat osteoblast-like cell cultures
without inducing changes in IGF-I synthesis [210]. This supports
a role for growth hormone in bone metabolism by modulating the
biological functions of IGF-I through its binding proteins. There
is an undefined influence of the parathyroid hormone and 1,25
dihydroxyvitamin D axis on bone IGF-I metabolism because
parathyroid hormone enhances the transcription and release of
IGF-I in bone cell cultures [211, 2121 and 1,25 dihydroxyvitamin D
increases IGF-I receptors in clonal osteoblastic cells [213].
There is also evidence linking growth hormone and IGF-I to
metabolism of calcium and phosphate in the kidney. Treatment
with growth hormone increases urinary calcium excretion in
humans [164] and stimulates proximal tubular reabsorption of
phosphate in both humans and experimental animals [154, 164,
2141. In addition, high circulating concentrations of 1,25 dihy-
droxyvitamin D have been reported in acromegalic individuals
[215] and elderly people receiving growth hormone administra-
tion [216]. This effect is likely mediated by IGF-I because, in
hypophysectomized rats, IGF-I infusion has been shown to in-
crease 1,25 dihydroxyvitamin D concentrations [217] and restore,
in part, the responsiveness of serum 1,25 dihydroxyvitamin D to
phosphate deprivation which is abolished in untreated hypophy-
sectomized rats [218]. These findings are consistent with a IGF-I
stimulated activity of tubular 1 alpha-hydroxylase enzyme. Finally,
IGF-I stimulates vitamin D receptor expression of cultured
growth plate chondrocytes [219].
The activation of renal 1,25-dihydroxyvitamin D synthesis by
low dietary phosphate is blocked in hypophysectomized animals
[201]. This effect is restored by growth hormone treatment as well
as by IGF-1 administration [220]. The effectiveness of IGF-1 in
restoring the increased renal synthesis of 1,25-dihydroxyvitamin D
induced by dietary phosphate restriction indicates that, in this
respect, the IGF-1 again mediates the action of growth hormone
[220]. In addition, several lines of evidence point to the synergistic
effect of IGF-1 and 1,25-dihydroxyvitamin D3 and bone cell
proliferation and differentiation—steps necessary for bone growth
[221]. In osteoblast cells, growth hormone treatment increases
intracellular IGF-1, which leads to increased cell proliferation,
and DNA and protein synthesis in cultured rat calvaria [220].
1,25-dihydroxyvitamin D receptor gene expression is stimulated
by growth factors, including IGF-1. 1,25-dihydroxyvitamin D also
increases IGF-1 receptor. In addition, in the osteoblast cells,
1,25-dihydroxyvitamin D is shown to regulate the production of
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IGF-1 and IGF-1 binding protein, effectively controlling prolifer-
ation and enhancing differentiation [221].
Another major effect of growth hormone relevant to chronic
uremia is that growth hormone administration in uremia induced
a shift in the target cells from proliferative to hypertrophic zone
[222]. It was found that growth hormone administration stimu-
lates the more mature hypertrophic chondrocyte instead of the
immature proliferating chondrocytes [222]. Growth hormone and
IGF-I can both stimulate all phases of chondrocyte differentiation
[207], although IGF-I is not as effective as growth hormone [207].
Growth hormone stimulates renal la-hydroxylase activity, result-
ing in increased synthesis of 1,25-dihydroxyvitamin D [223].
Recent studies have provided convincing evidence for a role of
1,25-dihydroxyvitamin D in restoring the production of transform-
ing growth factor beta (TGF-13) which leads to osteoinduction
[224], in contrast to the lack of osteoinduction in vitamin D
deficiency. In other words, 1,25-dihydroxyvitamin D is required
for the synthesis of transforming growth factor, TGF-13. Thus
TGF-p is required in the osteoinduction process. These all point
to the intricate interrelationship of the growth factors enumerated
here on bone growth.
In chronic uremia, the destruction of renal tissue gives rise to
impaired synthesis of 1,25-dihydroxyvitamin D, resulting in a
decrease in its serum concentration. This usually occurs when the
glomerular filtration rate is less than 50% of normal for age. How
this diminished 1,25-dihydroxyvitamin D affects TGF-13 synthesis
is just beginning to be explored. Finally, it has been observed that
in anephric patients, who were on dialysis, recombinant human
growth hormone might have a diminished effectiveness in promot-
ing growth, possibly due to decreased 1,25-dihydroxyvitamin D
production.
Exogenously administered growth hormone has been shown to
promote growth in uremic children [225—228]. However, only
pharmacological dosages of recombinant human growth hormone
were found to be effective. As indicated earlier, it has recently
been suggested that the depressed TGF-j3 in vitamin D deficiency
increased 100% with 1,25-dihydroxyvitamin D administration
[224]. It is possible that without adequate 1,25-dihydroxyvitamin
D, as often occurs in chronic renal failure, growth hormone might
fail to exert its full effect in the bone.
Recent animal experiments by Santos et al [174] in early
chronic renal insufficiency, showed growth failure was secondary
to caloric insufficiency and the growth response to recombinant
growth hormone was less dramatic, whereas in advanced uremia,
growth hormone treatment enhanced food efficiency and pro-
moted significant growth. In addition, steroid-induced growth
retardation was reversible with exogenous human recombinant
growth hormone [229].
Conjoint use of growth hormone and 1,25-dihydroxyvitamin D
in uremic rats has been shown to be associated with increased
hypercalciuria [230], even when the 1,25-dihydroxyvitamin D and
recombinant human growth hormone were used at therapeutic
dosages.
Clinical use of recombinant growth hormone in chronic
renal insufficiency
Fine [231], Tonshoff et al [226], and Hokken-Koelega et al [228]
demonstrated significant growth acceleration in uremic children
treated with recombinant human growth hormone therapy. The
recommended dosage of recombinant human growth hormone
was 0.3 to 0.4 mg/kg body wt/week in three equal divided dosages.
Intraperitoneal administration of 0.05 mg/kg body wt/day also
improved the short stature in a small number of children [232] and
adults [2331 on chronic peritoneal dialysis. In children after renal
transplantation, growth hormone therapy at 0.3 to 0.4 mg/kg body
wt/week was recommended, together with continuation of all
immunosuppressive therapy [180, 231, 234]. The serum IGF-
binding protein-3, which was already elevated in chronic renal
failure, rose to even higher concentrations after growth hormone
administration. In chronic renal failure, IGFBP-6 was notably
elevated, and this decreased after renal transplantation [235].
Because excess IGFBPs likely interferes with attainment of renal
growth [189], the decrease of excess IGFBP-6 after renal trans-
plant [235] may be causally associated with better growth poten-
tial. Growth hormone-binding activity is low in uremic children
[191]. This does not change with growth hormone therapy,
although enhanced growth velocity and serum insulin-like growth
factor concentration increased significantly with growth hormone
administration [191].
In relation with the effect of growth hormone administration on
thyroid function, Moller et al [236] demonstrated that growth
hormone administered for 14 days to normal adults elevates
energy expenditure, and suggest that this effect may be mediated
by an increase in peripheral T4 and T3 conversion. Administration
of IGF-I and insulin to healthy young adults has been shown to
increase glucose uptake and oxidation and suppress glucose
production, free fatty acid concentrations and fat oxidation rates
in a similar manner [237]. On the other hand, rhIGF-I adminis-
tered as an intravenous bolus to healthy humans produces a
hypoglycemic response [238] and decreases plasma insulin levels
[239]. Nevertheless, the hypoglycemic effect of IGF-I is likely due
to supraphysiologic concentrations of free circulating IGF-I, an
unlikely situation in patients with chronic renal failure, in whom
serum IGFBP concentrations are in relative excess to IGF-I.
Recombinant human insulin-like growth factor-I (rhIGF-I) has
been used in patients with end-stage renal failure [240, 241],
resulting in enhanced inulin and PAH clearance but declining
IGF binding protein-3. Complications include tachycardia, Bell's
palsy, papilledemia, and hypoglycemia. These side effects were
dose-dependent and may be avoided by dose reduction [240]. In
uremic rats, the conjoint use of IGF-I and growth hormone
significantly increased body growth while reducing serum concen-
tration of insulin and cholesterol [242].
In patients on maintenance peritoneal [243] or hemodialysis
[244], the use of rhIGF-I promotes positive protein balance and
may be efficacious in the treatment of malnutrition in these
patients [245]. Despite these reports on the positive responses of
patients with chronic renal failure, the deleterious effect on renal
structure and function in rat studies [246, 247] suggest that
caution is warranted in the use of growth hormone in patients with
severe glomerular diseases. High circulating concentrations of
growth hormone by itself may not cause renal damage, as
end-stage renal disease is not seen in higher frequency in ac-
romegolic subjects, but this may not apply in patients with
pre-existing renal diseases as suggested by the results of experi-
mental uremic studies [248, 249]. In summary, the growth failure
in chronic renal insufficiency, despite elevated serum growth
hormone concentration, is supportive of growth hormone resis-
tance in uremic humans [173] and in rats [182], and provides the
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rationale for using recombinant human growth hormone in ure-
mia. However, insulin-like growth factor is likely the better
therapeutic agent to achieve the desirable growth promotion
[249], without the potential of growth hormone-induced glomer-
uloscierosis [249], seen in mice transgenic to growth hormone and
not to insulin-like growth factor.
Human recombinant IGF-I administration in acute
renal failure
Because acute renal failure is associated with increased protein
breakdown, recombinant human IGF-I has been used as an
anti-catabolic agent in rats with ischemic acute renal failure
[250—254]. A slower rate of rise in creatinine plus increased renal
plasma flow and enhanced glomerular filtration rate suggest a
potential for this growth factor in the treatment of acute renal
failure. Finally, intraventricular IGF-1 administration given within
two hours of hypoxemic-ischemic brain injury reduced neuronal
death, with IGF-1 acting to block apoptosis [1881.
Human recombinant growth hormone or IGF-I in
nephrotic syndrome
Children with nephrotic syndrome suffer from increased urinary
losses of IGF carrying protein [255]. The depressed serum con-
centrations of IGF-I and IGF-II demonstrated by Garin, Grant
and Silverstein [255] may result partly from the loss of IGF
carrying protein in the massive proteinuria. In experimental
nephrotic syndrome, Thabet et al [256] demonstrated significant
depression of growth hormone receptor mRNA and IGF-receptor
mRNA in addition to reduced serum IGF-I, IGF-II, IGFBP-3 and
IGFBP-4. These results suggest that the growth retardation of
nephrosis may be due to the significant reduction in these growth
factors and IGF-receptor mRNA [256]. The growth retardation of
children with nephrotic syndrome, even before steroid treatment,
may be related to this lack of growth factors [255]; to reverse the
growth retardation by administration of growth hormone or IGF-I
in nephrotic syndrome required a close examination of the
risk/benefit ratio. In puromycin aminonucleoside nephrosis in
rats, Trachtman et al [2461 demonstrated that administration of
growth hormone exacerbates the severity of glomeruloscierosis.
Steroid-induced growth failure may respond to growth hormone
treatment, but the prednisone dose placed a limit on the range of
response [257].
Human recombinant growth hormone in X-linked
hypophosphatemic rickets
On the rationale that growth hormone promotes tubular reab-
sorption of phosphate and may enhance normalization of serum
phosphate concentration in patients with X-linked hypophos-
phatemic rickets, in addition to an independent effect to augment
growth at the growth plate of the long-bones, Wilson et al [258]
administered recombinant human growth hormone to the patients
with this disorder. Preliminary data [258] are encouraging, but
long-term clinical trials [259] are still in progress.
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